Clinical Trials Logo

Dermatitis, Atopic clinical trials

View clinical trials related to Dermatitis, Atopic.

Filter by:

NCT ID: NCT05911841 Recruiting - Atopic Dermatitis Clinical Trials

A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Start date: June 21, 2023
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).

NCT ID: NCT05905133 Active, not recruiting - Atopic Dermatitis Clinical Trials

A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD

Start date: July 15, 2023
Phase: Phase 2
Study type: Interventional

This study is a single-arm, open-label, multi-center clinical study designed to assess the safety and efficacy of CBP-201 in eligible subjects with moderate to severe Atopic Dermatitis.

NCT ID: NCT05904509 Completed - Atopic Dermatitis Clinical Trials

Insulin Resistance in Atopic Dermatitis Patients

Start date: September 1, 2022
Phase:
Study type: Observational

The aim of the study is to determine the relationship between insulin resistance and disease duration and severity of atopic dermatitis.

NCT ID: NCT05899816 Active, not recruiting - Atopic Dermatitis Clinical Trials

A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

ROCKET-VOYAGER
Start date: June 7, 2023
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to: - estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus response at Week 24 - estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-meningococcal response at Week 24

NCT ID: NCT05891119 Active, not recruiting - Atopic Dermatitis Clinical Trials

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

Start date: June 3, 2023
Phase: Early Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the pharmacokinetics (PK) of multiple cytochrome P450 (CYP450) substrates alone and in combination with rocatinlimab in participants with moderate to severe atopic dermatitis (AD).

NCT ID: NCT05882877 Recruiting - Atopic Dermatitis Clinical Trials

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

ROCKET-ASCEND
Start date: May 31, 2023
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

NCT ID: NCT05870865 Completed - Dermatitis, Atopic Clinical Trials

A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis

Start date: May 3, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate ASN008 in people with itch caused by eczema. The main questions it aims to answer are: - What is the efficacy and safety of ASN008? - What is the impact of ASN008 on itch in patients with atopic dermatitis? Participants will be asked to apply topical ASN008, or matching vehicle (placebo containing no active drug), to their eczema lesions twice daily for 4 weeks. Researchers will compare 3 different doses of ASN008 and a matching vehicle group to see which group responds best.

NCT ID: NCT05868824 Recruiting - Atopic Dermatitis Clinical Trials

Dynamic Blood Inflammatory Profile in Atopic Dermatitis Patients (ADAMUNE)

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

This is a prospective, single-center, class 2 study to better characterize the immune response in immune response in the blood of atopic dermatitis. Investigators are following in the referral center of Nice, 100 patients with atopic dermatitis. Investigators plan to include 30 patients. Blood samples will be collected to assess cytokine levels after non-specific immune stimulation. immune stimulation. Whole blood will be collected and stimulated with immune ligands (anti-CD3 T-cell stimulating ligands associated with Thymic Stromal LymphoPoietin (TSLP) or TLR agonist R848 7/8 agonist stimulating NK (natural killer) lymphocytes and promoting T cell response) on lyophilized freeze-dried spheres (LyoSphere, Qiagen) within 8 hours of blood collection.

NCT ID: NCT05859724 Recruiting - Atopic Dermatitis Clinical Trials

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Start date: May 10, 2023
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, single- and multiple ascending dose study of subcutaneous (SC) administration of NM26-2198 in healthy volunteers and adult patients with moderate to-severe AD to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single (SAD) and multiple doses (MAD) of NM26-2198.

NCT ID: NCT05844618 Recruiting - Atopic Dermatitis Clinical Trials

Short-Term Efficacy of Triamcinolone Acetonide (Aristocort® C) in Subjects With Atopic Dermatitis

Start date: May 9, 2023
Phase: Phase 4
Study type: Interventional

This study is a randomized, intraindividual study to evaluate the short-term efficacy of triamcinolone acetonide (Aristocort® C) in subjects with atopic dermatitis.